Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06870136 · ClinicalTrials.gov registry record
Study Evaluating the Quality and Effects of Lion's Mane Product on Cognitive Health
A clinical trial of Cognitive Decline, sponsored by M2 Ingredients.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT06870136: Recruiting study of Cognitive Decline, sponsored by M2 Ingredients.
NCT06870136 is a study of Cognitive Decline that is actively recruiting participants, run by M2 Ingredients. The registered enrollment target is 150 participants, below the 1,147-participant average among 61 other Cognitive Decline trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06870136, a study of Cognitive Decline, is actively recruiting participants, sponsored by M2 Ingredients.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The rationale for this study is to observe differences in cognitive health outcomes such as short term memory and simple reaction time between a consumer-grade and commercially available Lion's mane mushroom product and a placebo control group. Additionally, the study aims to evaluate the impact of the product on cognitive function, mood, focus, motivation, sleep quality, and stress. A consumer-driven, decentralized observational clinical research study is therefore well-suited for evaluating the impact of this product in this population. The study will evaluate cognitive health outcomes in a broad age-range of adults who have chosen to try this product. The study will incorporate memory and cognitive function tests, participant reported outcome questionnaires and surveys. There is no "doctor-patient" relationship as part of this research since the participant as a consumer is making the informed choice to take the product and participate in the observational process with self-reported measures that can be done at home. Findings from this study will contribute knowledge toward the functional mushrooms and cognitive health and the design of future studies.
Primary Outcome
The primary outcome measure is to evaluate the impact of the Lion's Mane study product on a composite measure of Attention, Short Term \& Working Memory. This will be measured using the change from baseline in BrainHQ Cognitive Test Suite composite score at Week 8 between placebo and study product group.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Lion's Mane Study Product
Study Locations (1)
California
- People Science - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-02-21 |
| Est. Completion | 2025-09-17 |
What NCT06870136 shows while recruiting
NCT06870136 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,147-participant average among 61 other Cognitive Decline trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Cognitive Decline appearing as the primary indexed condition, and to 1 intervention - of which Lion's Mane Study Product is the first listed.
NCT06870136 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06870136 about?
NCT06870136 is a clinical study titled "Study Evaluating the Quality and Effects of Lion's Mane Product on Cognitive Health". The rationale for this study is to observe differences in cognitive health outcomes such as short term memory and simple reaction time between a consumer-grade and commercially available Lion's mane mushroom product and a placebo control group. Additionally, the study aims to evaluate the impact of ...
What is the current status of trial NCT06870136?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2025-02-21. Estimated completion is 2025-09-17.
What conditions does trial NCT06870136 study?
This clinical trial studies the following conditions: Cognitive Decline.
What interventions are being tested in trial NCT06870136?
The interventions under investigation include: Lion's Mane Study Product (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06870136?
This trial is sponsored by M2 Ingredients, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06870136 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Decline
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06870136's enrollment target sits among peer trials
150 31st of 61 higher than 29 of 61 other Cognitive Decline trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Decline trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)
RECRUITING · Phase 1
-
mPATH for Low-income Older Adults
RECRUITING · NA
-
Older Breast Cancer Patients: Risk for Cognitive Decline
RECRUITING
-
Biomarker Exploration in Aging, Cognition and Neurodegeneration
RECRUITING · Phase 3
-
Glucose Variability and Cognition in Prediabetes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI